IDH1 ‐mutated Crohn's disease‐associated small bowel adenocarcinomas: Distinctive pathological features and association with MGMT methylation and serrated‐type dysplasia
Histopathology · 2024-02 · 84 (3) · 515-524
DOI: 10.1111/his.15095 ↗Kurz gefasst
Fachartikel in der Zeitschrift Histopathology, online erschienen am 21.11.2023. Verfasst von Camilla Guerini und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine, Unit of Anatomic Pathology, University of Pavia, Pavia, Italy. Hauptthemen laut MEDLINE: Crohn Disease, Adenocarcinoma, Duodenal Neoplasms, Brain Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Italian Ministry of Health, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Fondazione Policlinico San Matteo, Pavia, Italy, Italian Ministry of Education, University and Research (MIUR).
Abstract (Originalsprache)
Aims
Patients with Crohn's disease (CrD) have an elevated risk for the development of small bowel adenocarcinomas (SBAs). Actionable isocitrate dehydrogenase 1 ( IDH1 ) mutations have been reported to be more frequent in CrD‐SBAs than in sporadic SBAs. The present study aimed to investigate the clinicopathological and immunophenotypical features, as well as methylation profiles, of IDH1 ‐mutated CrD‐SBAs. Methods and results An international multicentre series of surgically resected CrD‐SBAs was tested for IDH1 mutation. Clinicopathological features, immunophenotypical marker expression and O6‐methylguanine‐DNA methyltransferase ( MGMT ) and long interspersed nuclear element‐1 (LINE‐1) methylation were compared between IDH1 ‐mutated and IDH1 wild‐type CrD‐SBAs. Ten (20%) of the 49 CrD‐SBAs examined harboured an IDH1 mutation and all the mutated cancers harboured the R132C variant. Compared to IDH1 wild‐type cases, IDH1 ‐mutated CrD‐SBAs showed significantly lower rates of cytokeratin 7 expression ( P = 0.005) and higher rates of p53 overexpression ( P = 0.012) and MGMT methylation ( P = 0.012). All three dysplastic growths associated with IDH1 ‐mutated SBAs harboured the same IDH1 variant (R132C) of the corresponding invasive cancer, and all were of non‐conventional subtype (two serrated dysplastic lesions and one goblet cell‐deficient dysplasia). In particular, non‐conventional serrated dysplasia was significantly associated with IDH1 ‐mutated CrD‐SBAs ( P = 0.029). No significant cancer‐specific survival difference between IDH1 ‐mutated CrD‐SBA patients and IDH1 wild‐type CrD‐SBA patients was found (hazard ratio = 0.55, 95% confidence interval = 0.16–1.89; P = 0.313).
Conclusions
IDH1 ‐mutated CrD‐SBAs, which represent approximately one‐fifth of total cases, are characterised by distinctive immunophenotypical features and methylation profiles, with potential therapeutic implications. Moreover, IDH1 ‐mutated non‐conventional, serrated dysplasia is likely to represent a precursor lesion to such CrD‐SBAs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Medicine, Unit of Anatomic Pathology, University of Pavia, Pavia, Italy.
- Unit of Anatomic Pathology, Fondazione IRCCS San Matteo Hospital, Pavia, Italy.
- Pathology Unit, Department of Medicine and Technological Innovation, University of Insubria, Varese, Italy.
- Pathology Unit, Department of Surgical and Diagnostic Sciences, University of Genoa, Genoa, Italy.
- Ospedale Policlinico San Martino University Hospital, Genoa, Italy.
- Clinical Epidemiology and Biometry, IRCCS San Matteo Hospital Foundation, University of Pavia, Pavia, Italy.
ORCID-Profile: Federica Grillo, Marco V Lenti, Matteo Fassan, Alessandro Vanoli
Förderung
- Italian Ministry of Health
- Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Fondazione Policlinico San Matteo, Pavia, Italy
- Italian Ministry of Education, University and Research (MIUR)
- Department of Molecular Medicine of the University of Pavia
- Dipartimenti di Eccellenza (2018-2022)
- Ministero della Salute
- Department of Molecular Medicine, University of Pavia
Zitieren
APA
Guerini, C., Furlan, D., Ferrario, G., Grillo, F., Libera, L., Arpa, G., Klersy, C., Lenti, M. V., Riboni, R., Solcia, E., Fassan, M., Mastracci, L., Ardizzone, S., Moens, A., De Hertogh, G., Ferrante, M., Graham, R. P., Sessa, F., Paulli, M., …, & Vanoli, A. (2024). IDH1 ‐mutated Crohn's disease‐associated small bowel adenocarcinomas: Distinctive pathological features and association with MGMT methylation and serrated‐type dysplasia. Histopathology, 84(3), 515-524. https://doi.org/10.1111/his.15095
Vancouver
Guerini C, Furlan D, Ferrario G, Grillo F, Libera L, Arpa G, et al. IDH1 ‐mutated Crohn's disease‐associated small bowel adenocarcinomas: Distinctive pathological features and association with MGMT methylation and serrated‐type dysplasia. Histopathology. 2024;84(3):515-524. doi:10.1111/his.15095
BibTeX
@article{Guerini2024,
author = {Guerini, Camilla and Furlan, Daniela and Ferrario, Giuseppina and Grillo, Federica and Libera, Laura and Arpa, Giovanni and Klersy, Catherine and Lenti, Marco V and Riboni, Roberta and Solcia, Enrico and Fassan, Matteo and Mastracci, Luca and Ardizzone, Sandro and Moens, Annick and De Hertogh, Gert and Ferrante, Marc and Graham, Rondell P and Sessa, Fausto and Paulli, Marco and Di Sabatino, Antonio and Vanoli, Alessandro},
title = {IDH1 ‐mutated Crohn's disease‐associated small bowel adenocarcinomas: Distinctive pathological features and association with MGMT methylation and serrated‐type dysplasia},
journal = {Histopathology},
year = {2024},
volume = {84},
number = {3},
pages = {515--524},
doi = {10.1111/his.15095}
}
EUVIMED